Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autologous Transplant Autoimmune Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions
Stem Cell Transplantation, CD34 selection
Procedure · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced May 21, 2026, 5:56 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
22
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced May 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Alemtuzumab, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Seah Lim M.D.
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
hematopoietic stem cell transplantation
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit), Mesna, Methylprednisolone, G-CSF
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
15 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
anti-thymocyte globulin, cyclophosphamide, filgrastim, prednisone, peripheral blood stem cell transplantation, irradiation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 21, 2026, 5:56 PM EDT
Withdrawn Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions
Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced May 21, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Depletion of CD3/CD19 in an autologous stem cell transplant
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
8 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis, Rheumatoid Arthritis
Interventions
Augment® Injectable Bone Graft, Autologous bone graft
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Columbus, Ohio • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions
mHSCT, cyclophosphamide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced May 21, 2026, 5:56 PM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 58 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced May 21, 2026, 5:56 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
Other · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 58 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Degenerative Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis & Other Inflammatory Polyarthropathies, Rheumatoid Arthritis of Subtalar Joint
Interventions
Subtalar Arthrodesis
Procedure
Lead sponsor
AlloSource
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
5
States / cities
Baltimore, Maryland • Grand Rapids, Michigan • Edina, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Stem Cell Transplanataion
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 5:56 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced May 21, 2026, 5:56 PM EDT